TR200100373T2 - İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri - Google Patents

İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri

Info

Publication number
TR200100373T2
TR200100373T2 TR2001/00373T TR200100373T TR200100373T2 TR 200100373 T2 TR200100373 T2 TR 200100373T2 TR 2001/00373 T TR2001/00373 T TR 2001/00373T TR 200100373 T TR200100373 T TR 200100373T TR 200100373 T2 TR200100373 T2 TR 200100373T2
Authority
TR
Turkey
Prior art keywords
antigens
hsv
cells
prevention
treatment
Prior art date
Application number
TR2001/00373T
Other languages
English (en)
Inventor
M. Koelle David
Corey Lawrence
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of TR200100373T2 publication Critical patent/TR200100373T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Bulus, HSV enfeksiyonunun önlenmesi ve tedavisi edilmesi için yararli olan HSV antijenleri saglamaktadir. Burada, herpetik lezyonlardan veya rahim boynundan türetilen T-hücreleri tarafindan baglandiklari teyit edilen antijenler ve/veya bunlari olusturan epitoplar tarif edilmektedir. Bulusun antijenlerine karsi özgünlügü olan T-hücreleri viral olarak sifrelenmis peptid epitoplari ile yüklenmis hücrelere karsi, ve bir çok durumda HSV bulasmis hücrelere karsi sitotoksik aktivite göstermistir. T-hücresi özgünlügünde sorumlu imünojenik antijenlerin belirlenmesi gelismis antiviral tedavi edici ve önleyici stratejilerle saglanir. Bulusun antijenlerini veya bunlari sifreleyen polinükleotidleri içeren bilesimler HSV enfeksiyonunun önlenmesi ve tedavisi için etkili asilar saglar.
TR2001/00373T 1998-08-07 1999-08-05 İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri TR200100373T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9572498P 1998-08-07 1998-08-07
US9572398P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
TR200100373T2 true TR200100373T2 (tr) 2001-09-21

Family

ID=26790525

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00373T TR200100373T2 (tr) 1998-08-07 1999-08-05 İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri

Country Status (16)

Country Link
US (5) US6375952B1 (tr)
EP (2) EP1102790B1 (tr)
JP (1) JP2002522451A (tr)
KR (1) KR20010085348A (tr)
CN (1) CN1348463A (tr)
AR (1) AR020134A1 (tr)
AU (1) AU5467899A (tr)
BR (1) BR9912671A (tr)
CA (1) CA2336523C (tr)
DK (1) DK2272859T3 (tr)
IL (1) IL141044A0 (tr)
NO (1) NO20010576L (tr)
NZ (1) NZ509974A (tr)
PL (1) PL346213A1 (tr)
TR (1) TR200100373T2 (tr)
WO (1) WO2000008051A2 (tr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1102790B1 (en) * 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
BRPI0107736B8 (pt) 2000-01-21 2021-05-25 Biovex Ltd cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2191845A1 (en) * 2001-07-31 2010-06-02 University of Washington Immunology significant herpes simplex virus antigens and methods for using same
EP2865386B1 (en) * 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US8871223B2 (en) * 2006-09-08 2014-10-28 The Trustees Of The University Of Pennsylvania HSV-1 and HSV-2 vaccines and methods of use thereof
WO2008124055A1 (en) * 2007-04-04 2008-10-16 The Board Of Trustees Of The University Of Arkansas Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
MX2011012347A (es) * 2009-05-22 2012-02-21 Genocea Biosciences Inc Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
US20130224236A1 (en) * 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
BR112013020875A2 (pt) 2011-02-15 2019-09-24 Immune Design Corp método para indução de uma resposta imune específica para um imunógeno em um indivíduo.
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) * 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccine against HSV-2
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
AU2015218365A1 (en) 2014-02-14 2016-09-01 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
AU2015289773A1 (en) 2014-07-15 2017-02-02 Immune Design Corp. Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
KR20160073707A (ko) 2014-12-17 2016-06-27 삼성중공업 주식회사 액화천연가스 운반선의 운용방법
EP3261654B1 (en) 2015-02-26 2021-08-11 Squarex, LLC Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
ES2900364T3 (es) * 2016-02-01 2022-03-16 Simplexia Ab Glicoproteína G truncada del virus del herpes simple tipo 2
KR20230051601A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
DK3596116T3 (da) 2017-03-16 2023-11-27 Alpine Immune Sciences Inc Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用
US20190031739A1 (en) * 2017-07-30 2019-01-31 Raymond Joel Rairie Pinball herpes antibody system
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020061376A2 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
SG11202111033VA (en) 2019-04-17 2021-11-29 Alpine Immune Sciences Inc Methods and uses of variant icos ligand (icosl) fusion proteins
AU2021267276A1 (en) 2020-05-08 2022-12-15 Alpine Immune Sciences, Inc. April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
CN115808528B (zh) * 2022-09-21 2023-08-01 武汉滨会生物科技股份有限公司 溶瘤单纯疱疹病毒vp5蛋白与人白细胞抗原e的互作方法及应用
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
EP0297924A3 (en) * 1987-07-01 1990-07-11 City Of Hope Recombinant vaccinia virus expressing hsv 1 gb
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
JPH05236967A (ja) * 1991-05-07 1993-09-17 Medical Res Council ヘルペスウイルス粒子及びワクチン
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
DE69636068T2 (de) * 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. Virale zubereitungen, vektoren, immunogene und impfstoffe
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2227786A1 (en) 1995-07-28 1997-02-13 Marie Curie Cancer Care Transport proteins and their uses
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
WO1998020016A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
EP0984790A1 (en) * 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
EP1102790B1 (en) * 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
GB9825953D0 (en) * 1998-11-26 1999-01-20 Medical Res Council Protein fragments for use in protein targeting
BR0014408A (pt) * 1999-09-30 2002-07-02 Univ Washington Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
EP2865386B1 (en) * 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
EP2521786B1 (en) * 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines

Also Published As

Publication number Publication date
US6855317B2 (en) 2005-02-15
EP1102790B1 (en) 2014-05-07
JP2002522451A (ja) 2002-07-23
US7744903B2 (en) 2010-06-29
US8067010B2 (en) 2011-11-29
US20100215693A1 (en) 2010-08-26
WO2000008051A3 (en) 2000-08-03
AU5467899A (en) 2000-02-28
US20120027790A1 (en) 2012-02-02
CA2336523C (en) 2015-06-30
EP2272859B1 (en) 2014-10-22
DK2272859T3 (en) 2015-01-19
US20050163794A1 (en) 2005-07-28
NO20010576L (no) 2001-04-02
EP2272859A3 (en) 2011-06-08
NZ509974A (en) 2003-10-31
EP2272859A2 (en) 2011-01-12
KR20010085348A (ko) 2001-09-07
WO2000008051A2 (en) 2000-02-17
EP1102790A2 (en) 2001-05-30
PL346213A1 (en) 2002-01-28
US20030118611A1 (en) 2003-06-26
CN1348463A (zh) 2002-05-08
BR9912671A (pt) 2001-05-02
CA2336523A1 (en) 2000-02-17
IL141044A0 (en) 2002-02-10
US8852602B2 (en) 2014-10-07
NO20010576D0 (no) 2001-02-02
US6375952B1 (en) 2002-04-23
AR020134A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
TR200100373T2 (tr) İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
PL355265A1 (en) Immunologically significant herpes simplex virus antigens
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
US9284355B2 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
JP2003535043A5 (tr)
DK2011510T3 (da) Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
CA2282300A1 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
Kim et al. Overview analysis of adjuvant therapies for melanoma—a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials
TR199801531T2 (tr) Zoster virüs geni ve ürününe karsi asilar.
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
Esterhuysen The antigenic variation of foot-and-mouth disease viruses and its significance in the epidemiology of the disease in southern Africa.
Lasky From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
Babu et al. Cancer vaccine: a review
TR200102388T2 (tr) Kronik viral enfeksiyonların m. vaccae ile tedavisi.
GR3029523T3 (en) Peptides that block human immunodeficiency virus infections and methods of use thereof
JP2003321391A (ja) 組換えワクシニアウイルスを用いたｈｉｖワクチン
Allen et al. 720. EGFRvIII Retargeted Oncolytic Measles Virus Strains Have Significant Antitumor Activity Against Gliomas
SONDERGAARD SR et al. patients mobilised similar numbers of CD4* T cells. Finally, no evidence was found for the existence of
YUASA et al. Skin Reactions to Vaccinia Virus Infection in the Rabbits Immunized with Vaccinia-soluble Early Antigen
US20110059127A1 (en) Use of mutant hiv-1 protease or siv protease as an adjuvant
CY1107607T1 (el) Νουκλεοπρωτεϊνη ιου toscana